Menu
← Oncology Approval Tracker
FDA DECISION ·
Iclusig
ponatinib · Takeda Pharmaceuticals USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with chronic-phase chronic myeloid leukemia resistant to or intolerant of at least two prior kinase inhibitors, with a response-based reduction in dose for the labeled regimen.
LAMPGEN ANALYSIS
Why it matters
Revised eligibility, introduced a response-adapted schedule for chronic-phase disease and added a 10 mg strength.
What research teams should watch
Set up BCR::ABL1 molecular response monitoring and review vascular risk and dose changes.
PRIMARY RECORDS